autologous dendritic cell-adenovirus CCL21 vaccine

BIOLOGICAL3 trials

Sponsors

Jonsson Comprehensive Cancer Center, H. Lee Moffitt Cancer Center and Research Institute

Conditions

Lung CancerLung Non-Small Cell CarcinomaMelanoma (Skin)Stage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8

Phase 1

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

CompletedNCT00601094

Jonsson Comprehensive Cancer CenterLung Cancer

Start: 2009-02-26End: 2017-05-23Updated: 2020-08-03

Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured

CompletedNCT00798629

H. Lee Moffitt Cancer Center and Research InstituteMelanoma (Skin)

Start: 2008-11-30End: 2012-04-30Updated: 2012-09-24

CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer

Active, not recruitingNCT03546361

Jonsson Comprehensive Cancer CenterLung Non-Small Cell Carcinoma, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8 +1

Start: 2019-07-08End: 2027-01-11Updated: 2025-01-14

Related Papers

Abstract 1605: Motif neoepitopes demonstrate immunogenic signal in CCL21-gene modified dendritic cell vaccination trial (NCT03546361)

Cancer Research2026-04-03

Abstract CT153: Phase I trial of intratumoral administration of autologous <i>CCL21</i> gene-modified dendritic cells in combination with pembrolizumab for advanced NSCLC: Feasibility of repeated IT injections

Cancer Research2024-04-051 citations

Abstract CT219: Phase I trial of <i>in situ</i> vaccination with autologous <i>CCL21</i> gene-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced non-small cell lung cancer (NSCLC)

Cancer Research2022-06-151 citations

Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC.

Journal of Clinical Oncology2022-06-01

Phase I trial of <i>in situ</i> vaccination with autologous <i>CCL21</i>-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC.

Journal of Clinical Oncology2021-05-202 citations

Abstract CT226: A Phase I trial of <i>in situ</i> vaccination with autologous <i>CCL21</i>-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC

Cancer Research2019-07-01

Abstract CT226: A Phase I trial of<i>in situ</i>vaccination with autologous<i>CCL21</i>-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC

Clinical Trials2019-07-01